Advanced Search

    Technical Analysis for PTN - Palatin Technologies, Inc.

    Grade Last Price % Change Price Change
    F 3.86 -3.02% -0.12
    PTN closed down 1.0 percent on Friday, February 3, 2023, on 55 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
    Earnings due: Feb 13
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical PTN trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish -3.02%
    Doji - Bullish? Reversal -3.02%
    Stochastic Reached Oversold Weakness -3.02%
    Oversold Stochastic Weakness -3.02%
    Shooting Star Candlestick Bearish -3.98%
    20 DMA Support Bullish -3.98%
    Wide Bands Range Expansion -3.98%
    20 DMA Support Bullish -5.16%
    Wide Bands Range Expansion -5.16%
    MACD Bearish Signal Line Cross Bearish -3.02%
    Older End-of-Day Signals for PTN ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Down 3% about 5 hours ago
    Fell Below Previous Day's Low about 6 hours ago
    Down 2 % about 6 hours ago
    20 DMA Resistance about 6 hours ago
    Down 1% about 6 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators Basic chart:

    Profile

    Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Dysfunction Endocrine System Obesity Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity

    Is PTN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 2 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 26 Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
    Jan 19 Palatin starts mid-stage study of bremelanotide for diabetic kidney disease
    Jan 19 Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
    Jan 18 Palatin secures $4.7M of non-dilutive funding
    Jan 18 Palatin Receives $4.7 Million of Non-Dilutive Funding
    Jan 10 Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions
    Jan 5 Palatin Technologies up 17% on prelim FQ2 results
    Jan 5 Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
    Nov 14 Palatin Technologies, Inc. (PTN) Q1 2023 Earnings Call Transcript
    Nov 14 Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates
    See more PTN news...

    Indicators

    Indicator Value
    52 Week High 13.0
    52 Week Low 2.14
    Average Volume 74,490
    200-Day Moving Average 6.08
    50-Day Moving Average 3.58
    20-Day Moving Average 4.06
    10-Day Moving Average 4.11
    Average True Range 0.44
    RSI 53.05
    ADX 40.03
    +DI 24.95
    -DI 10.64
    Chandelier Exit (Long, 3 ATRs) 3.69
    Chandelier Exit (Short, 3 ATRs) 3.87
    Upper Bollinger Bands 4.66
    Lower Bollinger Band 3.46
    Percent B (%b) 0.43
    BandWidth 29.66
    MACD Line 0.15
    MACD Signal Line 0.18
    MACD Histogram -0.0317
    Fundamentals Value
    Market Cap 915.01 Million
    Num Shares 230 Million
    EPS 0.15
    Price-to-Earnings (P/E) Ratio 26.36
    Price-to-Sales 792.23
    Price-to-Book 1.34
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.51
    Resistance 3 (R3) 4.54 4.40 4.42
    Resistance 2 (R2) 4.40 4.27 4.38 4.39
    Resistance 1 (R1) 4.19 4.18 4.12 4.16 4.36
    Pivot Point 4.05 4.05 4.02 4.03 4.05
    Support 1 (S1) 3.84 3.92 3.77 3.81 3.60
    Support 2 (S2) 3.70 3.83 3.68 3.57
    Support 3 (S3) 3.49 3.70 3.54
    Support 4 (S4) 3.46